Literature DB >> 15455382

Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.

Sorina Grisaru-Granovsky1, Zaidoun Salah, Myriam Maoz, Diana Pruss, Uziel Beller, Rachel Bar-Shavit.   

Abstract

Protease activated receptors (PAR) form a family of G-protein coupled receptors (GPCR) encoding their own ligands and uniquely activated via proteolytic cleavage. Although proteases in general have been implicated in the remodeling of the extracellular tumor microenvironment, the role of cell surface receptors activated by proteolysis is now emerging. In our present study we investigated the expression pattern of protease activated receptor 1 hPar1 in ovarian carcinoma tissue samples. Abundant hPar1 mRNA and protein were detected in "low malignant potential" and in invasive carcinomas, regardless of the histological subtype. In contrast, no hPar1 expression was detected on the cell surface of normal ovarian epithelium. The differential expression pattern of hPar1 was shown by in situ hybridization, immunohistochemistry and semi-quantitative RT-PCR analyses. In early stages of ovarian carcinoma (Ia), the contra lateral normal ovary showed strong PAR1 expression as opposed to the lack of expression in the ovarian epithelium obtained from normal individuals. In parallel, we analyzed the expression pattern of alphavbeta5 integrin and of activated focal adhesion kinase (FAK), a major focal contact protein, in these tissues. Although abundant expression of alphavbeta5 integrin was observed in all tissues specimens examined, regardless of either normal or malignant, the level of activated FAK was differentially expressed. Phosphorylated FAK was seen in invasive ovarian carcinoma, but not in the normal ovarian epithelium. The abundant hPar1 levels in pathological malignant ovarian carcinoma is likely to transmit signals leading to the phosphorylation of FAK and thereby alterations in the integrin functional state. Altogether our data suggest that hPar1 and FAK cooperate to promote ovarian cancer malignancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15455382     DOI: 10.1002/ijc.20607

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.

Authors:  Alice Chanakira; Pamela R Westmark; Irene M Ong; John P Sheehan
Journal:  Gynecol Oncol       Date:  2017-01-29       Impact factor: 5.482

2.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Authors:  Anika Agarwal; Lidija Covic; Leila M Sevigny; Nicole C Kaneider; Katherine Lazarides; Gissou Azabdaftari; Sheida Sharifi; Athan Kuliopulos
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Extracellular pressure stimulates adhesion of sarcoma cells via activation of focal adhesion kinase and Akt.

Authors:  Brandon C Perry; Shouye Wang; Marc D Basson
Journal:  Am J Surg       Date:  2010-11       Impact factor: 2.565

Review 4.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.

Authors:  Duangmani Thanapprapasr; Wei Hu; Anil K Sood; Robert L Coleman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Authors:  S Karabulut; E Akşit; F Tas; R Ciftci; A Aydiner; I Yildiz; S Keskin; Y Eralp; C T Yasasever; S Vatansever; R Disci; P Saip
Journal:  Tumour Biol       Date:  2014-01-05

6.  Mechanotransduction of fluid stresses governs 3D cell migration.

Authors:  William J Polacheck; Alexandra E German; Akiko Mammoto; Donald E Ingber; Roger D Kamm
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

7.  Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.

Authors:  Irit Cohen; Myriam Maoz; Hagit Turm; Sorina Grisaru-Granovsky; Bella Maly; Beatrice Uziely; Einat Weiss; Rinat Abramovitch; Eithan Gross; Oded Barzilay; Yun Qiu; Rachel Bar-Shavit
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

8.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

9.  Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.

Authors:  Eric Yang; Adrienne Boire; Anika Agarwal; Nga Nguyen; Katie O'Callaghan; Powen Tu; Athan Kuliopulos; Lidija Covic
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

10.  OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization.

Authors:  Fazal H Tabassam; David Y Graham; Yoshio Yamaoka
Journal:  Cell Microbiol       Date:  2007-12-06       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.